Kara C Long Roche

List of Publications by Year
in descending order

62	1,648	331670 21	330143 37
papers	citations	h-index	g-index

65	65	65	1961
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Risk-Reducing Bilateral Salpingo-Oophorectomy for Ovarian Cancer: A Review and Clinical Guide for Hereditary Predisposition Genes. JCO Oncology Practice, 2022, 18, 201-209.	2.9	34
2	Assessment of wound perfusion with near-infrared angiography: A prospective feasibility study. Gynecologic Oncology Reports, 2022, 40, 100940.	0.6	1
3	Gynecologic Survivorship Tool: Development, Implementation, and Symptom Outcomes. JCO Clinical Cancer Informatics, 2022, 6, e2100154.	2.1	2
4	Hyperthermic intraperitoneal chemotherapy (HIPEC) with carboplatin induces distinct transcriptomic changes in ovarian tumor and normal tissues. Gynecologic Oncology, 2022, 165, 239-247.	1.4	9
5	Risk factors for financial toxicity in patients with gynecologic cancer. American Journal of Obstetrics and Gynecology, 2022, 226, 817.e1-817.e9.	1.3	20
6	Ovarian cancer recurrence detection may not require in-person physical examination: an MSK team ovary study. International Journal of Gynecological Cancer, 2022, 32, 159-164.	2.5	10
7	CT of Ovarian Cancer for Primary Treatment Planning: What the Surgeon Needs to Knowâ€"Radiology In Training. Radiology, 2022, 304, 516-526.	7.3	4
8	Multimodal data integration using machine learning improves risk stratification of high-grade serous ovarian cancer. Nature Cancer, 2022, 3, 723-733.	13.2	82
9	Survival outcomes of acute normovolemic hemodilution in patients undergoing primary debulking surgery for advanced ovarian cancer: A Memorial Sloan Kettering Cancer Center Team Ovary study. Gynecologic Oncology, 2021, 160, 51-55.	1.4	2
10	Advanced ovarian cancer and cytoreductive surgery: Independent validation of a risk-calculator for perioperative adverse events. Gynecologic Oncology, 2021, 160, 438-444.	1.4	9
11	Salpingectomy for the Risk Reduction of Ovarian Cancer: Is It Time for a Salpingectomy-alone Approach?. Journal of Minimally Invasive Gynecology, 2021, 28, 403-408.	0.6	9
12	The association between tumor mutational burden and prognosis is dependent on treatment context. Nature Genetics, 2021, 53, 11-15.	21.4	139
13	Pretreatment neutrophil-to-lymphocyte ratio and mutational burden as biomarkers of tumor response to immune checkpoint inhibitors. Nature Communications, 2021, 12, 729.	12.8	212
14	Exploring the clinical significance of serous tubal intraepithelial carcinoma associated with advanced high-grade serous ovarian cancer: A Memorial Sloan Kettering Team Ovary Study. Gynecologic Oncology, 2021, 160, 696-703.	1.4	2
15	Outcomes of incidentally detected ovarian cancers diagnosed at time of risk-reducing salpingo-oophorectomy in BRCA mutation carriers. Gynecologic Oncology, 2021, 161, 521-526.	1.4	2
16	Molecular characterization of high-grade serous ovarian cancers occurring in younger and older women. Gynecologic Oncology, 2021, 161, 545-552.	1.4	8
17	Frailty based on the memorial Sloan Kettering Frailty Index is associated with surgical decision making, clinical trial participation, and overall survival among older women with ovarian cancer. Gynecologic Oncology, 2021, 161, 687-692.	1.4	14
18	Risk of venous thromboembolism in ovarian cancer patients receiving neoadjuvant chemotherapy. Gynecologic Oncology, 2021, 163, 36-40.	1.4	18

#	Article	IF	Citations
19	Clinical outcomes of patients with endometrioid epithelial ovarian cancer following surgical treatment. Journal of Surgical Oncology, 2021, 124, 846-851.	1.7	0
20	Tertiary cytoreduction for recurrent ovarian carcinoma: An updated and expanded analysis. Gynecologic Oncology, 2021, 162, 345-352.	1.4	8
21	Quaternary and beyond cytoreduction: An updated and expanded analysis. Gynecologic Oncology Reports, 2021, 37, 100851.	0.6	1
22	Surgical ovarian suppression for adjuvant treatment in hormone receptor positive breast cancer in premenopausal patients. International Journal of Gynecological Cancer, 2021, 31, 222-231.	2.5	2
23	A perception-based nanosensor platform to detect cancer biomarkers. Science Advances, 2021, 7, eabj0852.	10.3	43
24	Minimally invasive surgery versus laparotomy for radical hysterectomy in the management of early-stage cervical cancer: Survival outcomes. Gynecologic Oncology, 2020, 156, 591-597.	1.4	54
25	Patient-reported outcomes after surgery for endometrial carcinoma: Prevalence of lower-extremity lymphedema after sentinel lymph node mapping versus lymphadenectomy. Gynecologic Oncology, 2020, 156, 147-153.	1.4	61
26	Role of delayed interval debulking for persistent residual disease after more than 5Âcycles of chemotherapy for primary advanced ovarian cancer. An international multicenter study. Gynecologic Oncology, 2020, 159, 434-441.	1.4	16
27	Video-assisted thoracic surgery in the primary management of advanced ovarian carcinoma with moderate to large pleural effusions: A Memorial Sloan Kettering Cancer Center Team Ovary Study. Gynecologic Oncology, 2020, 159, 66-71.	1.4	12
28	Comparison of minimally invasive versus open surgery in the treatment of endometrial carcinosarcoma. International Journal of Gynecological Cancer, 2020, 30, 1162-1168.	2.5	6
29	Pre-operative neoadjuvant chemotherapy cycles and survival in newly diagnosed ovarian cancer: what is the optimal number? A Memorial Sloan Kettering Cancer Center Team Ovary study. International Journal of Gynecological Cancer, 2020, 30, 1915-1921.	2.5	29
30	A multimodality triage algorithm to improve cytoreductive outcomes in patients undergoing primary debulking surgery for advanced ovarian cancer: A Memorial Sloan Kettering Cancer Center team ovary initiative. Gynecologic Oncology, 2020, 158, 608-613.	1.4	23
31	Practical guidelines for triage to neoadjuvant chemotherapy in advanced ovarian cancer: Big risk, big rewardâ€¦or too much risk?. Gynecologic Oncology, 2020, 157, 561-562.	1.4	2
32	A Molecularly Targeted Intraoperative Near-Infrared Fluorescence Imaging Agent for High-Grade Serous Ovarian Cancer. Molecular Pharmaceutics, 2020, 17, 3140-3147.	4.6	10
33	The impact of near-infrared angiography and proctoscopy after rectosigmoid resection and anastomosis performed during surgeries for gynecologic malignancies. Gynecologic Oncology, 2020, 158, 397-401.	1.4	7
34	Robotic Surgery in the Frail Elderly: Analysis of Perioperative Outcomes. Annals of Surgical Oncology, 2020, 27, 3772-3780.	1.5	16
35	Impact of provider volume on front-line chemotherapy guideline compliance and overall survival in elderly patients with advanced ovarian cancer. Gynecologic Oncology, 2020, 159, 418-425.	1.4	7
36	Characteristics and survival of ovarian cancer patients treated with neoadjuvant chemotherapy but not undergoing interval debulking surgery. Journal of Gynecologic Oncology, 2020, 31, e17.	2.2	22

#	Article	IF	Citations
37	Hematologic changes after splenectomy for ovarian cancer debulking surgery, and association with infection and venous thromboembolism. International Journal of Gynecological Cancer, 2020, 30, 1183-1188.	2.5	4
38	Update on the role of surgery in the management of advanced epithelial ovarian cancer. Clinical Advances in Hematology and Oncology, 2020, 18, 723-731.	0.3	3
39	State of the science: Evolving role of surgery for the treatment of ovarian cancer. Gynecologic Oncology, 2019, 155, 3-7.	1.4	7
40	Secondary surgical resection for patients with recurrent uterine leiomyosarcoma. Gynecologic Oncology, 2019, 154, 333-337.	1.4	14
41	Geriatric co-management leads to safely performed cytoreductive surgery in older women with advanced stage ovarian cancer treated at a tertiary care cancer center. Gynecologic Oncology, 2019, 154, 77-82.	1.4	24
42	A Thoughtful Pause for Sparing Oophorectomy. Urology, 2019, 129, 237.	1.0	0
43	Brain metastasis in epithelial ovarian cancer by BRCA1/2 mutation status. Gynecologic Oncology, 2019, 154, 144-149.	1.4	24
44	Understanding Inherited Risk in Unselected Newly Diagnosed Patients With Endometrial Cancer. JCO Precision Oncology, 2019, 3, 1-15.	3.0	7
45	Exploring the impact of income and race on survival for women with advanced ovarian cancer undergoing primary debulking surgery at a high-volume center. Gynecologic Oncology, 2018, 149, 43-48.	1.4	10
46	A prospective trial of acute normovolemic hemodilution in patients undergoing primary cytoreductive surgery for advanced ovarian cancer. Gynecologic Oncology, 2018, 151, 433-437.	1.4	16
47	Perioperative epidural use and survival outcomes in patients undergoing primary debulking surgery for advanced ovarian cancer. Gynecologic Oncology, 2018, 151, 287-293.	1.4	23
48	Continuous improvement in primary Debulking surgery for advanced ovarian cancer: Do increased complete gross resection rates independently lead to increased progression-free and overall survival?. Gynecologic Oncology, 2018, 151, 24-31.	1.4	64
49	Optimal primary management of bulky stage IIIC ovarian, fallopian tube and peritoneal carcinoma: Are the only options complete gross resection at primary debulking surgery or neoadjuvant chemotherapy?. Gynecologic Oncology, 2017, 145, 15-20.	1.4	55
50	A multicenter assessment of the ability of preoperative computed tomography scan and CA-125 to predict gross residual disease at primary debulking for advanced epithelial ovarian cancer. Gynecologic Oncology, 2017, 145, 27-31.	1.4	95
51	Riskâ€reducing salpingectomy: Let us be opportunistic. Cancer, 2017, 123, 1714-1720.	4.1	31
52	Feasibility, safety and clinical outcomes of cardiophrenic lymph node resection in advanced ovarian cancer. Gynecologic Oncology, 2017, 147, 262-266.	1.4	43
53	Surgical site infection reduction bundle in patients with gynecologic cancer undergoing colon surgery. Gynecologic Oncology, 2017, 147, 115-119.	1.4	31
54	Primary cytoreductive surgery and adjuvant hormonal monotherapy in women with advanced low-grade serous ovarian carcinoma: Reducing overtreatment without compromising survival?. Gynecologic Oncology, 2017, 147, 85-91.	1.4	74

#	Article	IF	Citations
55	Geographic disparities in the distribution of the U.S. gynecologic oncology workforce: A Society of Gynecologic Oncology study. Gynecologic Oncology Reports, 2017, 22, 100-104.	0.6	28
56	â€œLittle Big Thingsâ€• A Qualitative Study of Ovarian Cancer Survivors and Their Experiences With the Health Care System. Journal of Oncology Practice, 2016, 12, e974-e980.	2.5	14
57	Cited rationale for variance in the use of primary intraperitoneal chemotherapy following optimal cytoreduction for stage III ovarian carcinoma at a high intraperitoneal chemotherapy utilization center. Gynecologic Oncology, 2016, 142, 13-18.	1.4	2
58	Intraperitoneal chemotherapy after interval debulking surgery for advanced-stage ovarian cancer: Feasibility and outcomes at a comprehensive cancer center. Gynecologic Oncology, 2016, 143, 496-503.	1.4	12
59	Diverting ileostomy during primary debulking surgery for ovarian cancer: Associated factors and postoperative outcomes. Gynecologic Oncology, 2016, 142, 217-224.	1.4	42
60	Is It Time to Centralize Ovarian Cancer Care in the United States?. Annals of Surgical Oncology, 2016, 23, 989-993.	1.5	44
61	Predictive value of the Age-Adjusted Charlson Comorbidity Index on perioperative complications and survival in patients undergoing primary debulking surgery for advanced epithelial ovarian cancer. Gynecologic Oncology, 2015, 138, 246-251.	1.4	71
62	A comparison of primary intraperitoneal chemotherapy to consolidation intraperitoneal chemotherapy in optimally resected advanced ovarian cancer. Gynecologic Oncology, 2014, 134, 468-472.	1.4	10